Abstract: The invention relates to a composition comprising at least one specific mixture of molecules for use as a drug or nutritional product in the prevention and/or treatment of chronic inflammatory bowel diseases in humans or animals.

Abstract: The present invention relates to the use of gasdermin, in particular of gasdermin A, gasdermin B, gasdermin C, gasdermin D, DFNA5 or DFNB59 (or pejvakin), and more particularly pejvakin for modulating cellular redox homeostasis. A particularly preferred use of gasdermin, in particular of gasdermin A, gasdermin B, gasdermin C, gasdermin D, DFNA5 or DFNB59 (or pejvakin), and more particularly pejvakin in the context of the present invention is as an antioxidant. The present invention also concerns a virally-mediated gene therapy for restoring genetically-impaired auditory and vestibular functions in subjects suffering from an Usher syndrome. More precisely, this gene therapy takes advantage of an AAV2/8 vector expressing at least one USH1 gene product, preferably SANS.

Abstract: The invention relates to a fluorination process consisting in bringing an inorganic compound M into contact with an atmosphere comprising difluorine gas, the inorganic compound M being a garnet based on the elements Li, La, Zr, A and O and for which the relative composition of the Li, La, Zr and A cations corresponds to the formula (I): LixLa3ZrzAw.

Abstract: A mobile 3D printing device, system and method based on the addition of material intended to be attached to a lifting device with a single lifting cable or chain, including a printing head adapted to receive material and depositing it; fixing means adapted to link the printing head to the lifting device, and stabilization means adapted to stabilize the position of the printing head by a gyroscopic effect. The printing device enables the control of the printing of a structure to be printed, in particular the position of the printing head, to reduce the labor costs and the time to install such a device on a standard crane provided with a hook.

Abstract: The present invention concerns a process for isolating an archaeon of the order of commensal clade Methanomassiliicoccales, the use of a culture and/or isolation medium comprising a sterile extract of a bacterial culture of a bacterium of genus Eggerthella, for the isolation and/or culture of an archaeon of the order of commensal clade Methanomassiliicoccales, and a pure, isolated archaeon Methanomethylophilus alvus Mx-05. It also concerns a culture method of an archaeon of the order of commensal clade Methanomassiliicoccales.

Abstract: The present invention relates to a method for preparing phosphorylated keto polyols by biocatalysis and uses thereof.

Abstract: A method of manufacturing nanoparticles of a photoluminescent material, including the successive steps of: a) forming nanometer-range particles of said photoluminescent material; b) forming a dispersion containing the particles in a non-aqueous solvent, the dispersion further containing at least one surface agent; c) placing the dispersion in an autoclave at a pressure in the range from 2 MPa to 100 MPa; and d) recovering the particles.

Abstract: The invention relates to an active pharmaceutical ingredient consisting exclusively of the combination of (1S,3R,4R,5R)-3-{[(2E)-3-(3,4-)dihydroxyphenyl)-2-propenoyl]oxy}-1,4,5-trihydroxycyclohexanecarboxylic acid and of methyl (2S,3E,4S)-4-{2-[2-(3,4-dihydroxyphenyl)ethoxy]-2-oxoethyl}-3-ethylidene-2-(?-D-glucopyranosyloxy)-3,4-dihydro-2H-pyran-5-carboxylate for use as a drug or veterinary product, particularly in the prevention and/or treatment of pathological disorders of carbohydrate and/or lipid metabolism.

Abstract: Gastro-intestinal release capsule intended for oral use in a method for desensitizing and/or inducing tolerance in a peanut-allergic subject or, alternatively, for diagnosing a peanut allergy in a subject. The capsule has a shell and a core, the core has a composition of peanut including peanut, at least one oil, at least one first pulverulent excipient and, optionally, at least one second prebiotic excipient. The capsule is provided and ingested in an unopened form.

Abstract: A composition comprising at least a mixture of molecules extracted from Chrysanthellum indicum, Cynara scolymus and Lycium barbarum. This composition is in particular useful as a nutritional product or health product to prevent and/or combat fat and/or carbohydrate metabolism disorders in Humans or animals.

Abstract: The present invention relates to the use of gasdermin, in particular of gasdermin A, gasdermin B, gasdermin C, gasdermin D, DFNA5 or DFNB59 (or pejvakin), and more particularly pejvakin for modulating cellular redox homeostasis. A particularly preferred use of gasdermin, in particular of gasdermin A, gasdermin B, gasdermin C, gasdermin D, DFNA5 or DFNB59 (or pejvakin), and more particularly pejvakin in the context of the present invention is as an antioxidant. The present invention also concerns a virally-mediated gene therapy for restoring genetically-impaired auditory and vestibular functions in subjects suffering from an Usher syndrome. More precisely, this gene therapy takes advantage of an AAV2/8 vector expressing at least one USH1 gene product, preferably SANS.

Abstract: A composition comprising at least: a single extract obtained from a mixture of at least two plants selected from Chrysanthellum indicum, Cynara scolymus, Vaccinium myrtillus, Piper and Olea europaea. This composition is particularly useful as a nutritional product or health product for preventing and/or combating carbohydrate and/or fat metabolism disorders in humans and animals.

Abstract: A method for producing a photo-luminescent material, including the following steps: (1) producing, according to a sol-gel method, a sol and then a gel of first precursors of a first substance from the sol; (2) crushing the gel; (3) optionally, annealing the gel in order to form first particles of the first substance of which the average size is between 1 pm and 20 um; (4) producing a colloidal dispersion of second particles of a second substance, different from the first substance or identical to the first substance, of which the average size is between 5 nm and 400 nm; (5) mixing the colloidal dispersion with the sol in step (1) before forming the gel or with the first particles after step (3); and (6) annealing the mixture obtained in step (5), resulting in an increase in the compactness of the mixture, the average size of the second particles after annealing being between 100 nm and 900 nm.

Abstract: The invention relates to an implant material for filling bone defects, for bone regeneration, and for bone tissue engineering, to an implant comprising said material, and to methods for manufacturing such an implant. The hybrid implant material according to the invention comprises: a biodegradable polymer P soluble in at least one solvent S1 and insoluble in at least one solvent S, different from the solvent S1; and a bioactive glass made of SiO2 and CaO and optionally containing P2O5 and/or optionally doped with strontium, characterized in that said implant includes a layering of a porous part having more than 90% by number of pores whose largest dimension is greater than or equal to 100 ?m, and a dense part (2, 20, 200, 2000, 20000) having more than 80% by number of pores whose largest dimension is less than 50 ?m. The invention is useful in the field of bone regeneration, particularly in the field of bone tissue engineering.

Abstract: The present invention relates to mannose derivatives of formula (I): wherein R1 represents H, CO—(C1-C6)-alkyl or CO-alkylaryl, Y represents a single bond, CH2, O, NR3, S, A represents O, NH or S, X represents H and X? represents OH or X and X? taken together with the carbon atom bearing them form a CO group, R2 represents H, a linear or branched (C1-C6)-alkyl or CF3, R3 represents H, a C1-C6 alkyl, a CO—(C1-C6)-alkyl, CF3 or COCF3, and R is as described in claim 1.

Abstract: A composition including at least one XAP peptide, in which X represents the empty set or a valine, for use in the prevention and/or treatment of pathologies associated with alpha-glucosidase. Also, the use of a hydrolysate of at least one protein, the protein including or constituted by at least 0.05% to <5% or of at least 5% of XAP units, in which X represents the empty set or a valine, for use in the prevention and/or treatment of pathologies associated with alpha-glucosidase.

Abstract: A method of manufacturing nanoparticles of a photoluminescent material, including the successive steps of: a) forming nanometer-range particles of said photoluminescent material; b) forming a dispersion containing the particles in a non-aqueous solvent, the dispersion further containing at least one surface agent; c) placing the dispersion in an autoclave at a pressure in the range from 2 MPa to 100 MPa; and d) recovering the particles.

Abstract: A composition comprising at least a mixture of molecules obtained at least from: Chrysanthellum indicum, Cynara scolymus, and Vaccinium myrtillus and wherein the mixture of molecules also comprises piperine. The composition is particularly useful as a nutritional product or health product for preventing and/or combating carbohydrate and/or fat metabolism disorders in humans and animals.

Abstract: The present invention relates to the use of compounds for the treatment or prevention of pain in mammals, in particularly in human beings, and also to a process for preparing these compounds.

Abstract: The disclosure relates to an implant material for filling bone defects, for bone regeneration, and for bone tissue engineering, to an implant comprising this material, to a method for producing such an implant, and to a method for producing a hybrid material. The implant material comprises a hybrid material comprising: a bioactive glass M based on SiO2 and CaO, optionally containing P2O5 and/or optionally doped with strontium, and a biodegradable polymer P soluble in a solvent and chosen from among bioresorbable polysaccharides. The implant material has applications in the medical field.